Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Carbonxt Group - Appendix 4C (ASX:CG1)

To view the Quarterly cash flow report for entities subject to Listing Rule 4.7B, download the attached PDF.

Carbonxt Group - December 2021 Quarterly Activities Report (ASX:CG1)

Highlights -- Second consecutive positive operating cash flow quarter ($240k) -- Quarterly customer receipts of A$4.9m – equal to prior quarter, and up 39% from same period year ago. First...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the ASX leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 Decem...read more

Chimeric receives US patent covering CLTX CAR technology (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to announce that the United States Patent and Trademark ...read more

Carbonxt Group signs LOI with US water filtration company Glanris (ASX:CG1)

United States focused Cleantech company Carbonxt Group Ltd (ASX:CG1) (‘‘Carbonxt” or “the Company”) is pleased to announce that it has signed a Letter of Intent with Un...read more

Chimeric Therapeutics - Transformative Portfolio Expansion Presentation (ASX:CHM)

To view the presentation, download the attached PDF.

Chimeric Therapeutics - Webinar CHM Transforms Portfolio (ASX:CHM)

Chimeric has obtained the exclusive option to license the CORE-NK platform, a Clinically validated, Off the shelf, Robust, Enhanced Natural Killer cell platform from Case Western Reserve University...read more

Chimeric Therapeutics - CLTX CAR T data shows regional control of tumour recurrence (ASX:CHM)

CLTX CAR T clinical data highlighted in Keynote presentation on November 20th 75% disease control rate seen at lowest dose level with up to 8 weeks of durability Tumour recurrence prevented at ...read more

Carbonxt Group Secures New Powdered Activated Carbon Orders (ASX:CG1)

Total value of powdered activated carbon (‘PAC’) have almost doubled and now exceed ~$11m annually Revenue from new orders materialises from January 2022 and deliver a forecast gross ...read more

Chimeric Therapeutics - CLTX CAR T presents positive initial Phase 1 clinical data (ASX:CHM)

75% disease control rate seen at lowest dose level of CLTX CAR T cells CLTX CAR T was generally well tolerated with no dose limiting toxicities Persistence of CLTX CAR T cells shown throughout ...read more

First milestone on path to CDH17 CAR T clinical trial (ASX:CHM)

Phase 1 plasmid manufacturing commenced Phase 1 clinical trial for neuroendocrine & colorectal tumors planned for 2022 Positions Chimeric to have a minimum of two Phase 1 trials underway du...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

To view the report, download the attached PDF.

Carbonxt Group - September 2021 Quarterly Activities Report (ASX:CG1)

Highlights Quarterly customer receipts of A$4.9m – up 81% on the prior quarter and up 16% on the A$4.2m forecast provided in August of this year Positive operating cash flow quarter for ...read more

Carbonxt Group - Appendix 4C (ASX:CG1)

To view the Quarterly cash flow report for entities subject to Listing Rule 4.7B, download the attached PDF.

Chimeric Therapeutics - European patent granted for CLTX technology used in CHM 1101 (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce the European Patent Office’s decision to gra...read more

Viewing: 166 - 180 of 200 Previous | Next